Canada markets closed

Emerald Health Therapeutics, Inc. (EMHTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0390+0.0015 (+4.00%)
At close: 03:05PM EDT
Sign in to post a message.
  • s
    stockmarKEK
    i like the stock
  • R
    RSM
    Skye will acquire all of the issued and outstanding shares of Emerald in a share-for-share-transaction, as I expected. I think it's very good news for both companies.
  • V
    Vito Corleone
    Fake company, scam alert, stay away!!!!!
  • J
    Jason
    Good luck to all us bag holders that got hung out to dry.The upside is that there will be a change in name and direction.Maybe we get lucky and SKYE has a game changer drug.We can only hope.Until then we wait.
  • R
    RSM
    "Under the Arrangement, Skye will issue Emerald shareholders 1.95 shares of Skye’s common stock (the “Exchange Ratio”) in exchange for each Emerald share." You do the math.
  • R
    Razer Ramon
    Regulators should do something to protect naive investors from all the garbage out there. It’s like letting kids out to play on the highway
  • G
    Guderian
    Sorry folks, this is another scam. Punit Dhillon, is the CEO of Skye Bioscience Inc. He also sits on the board of directors. Another familiar name is Jim Heppell, who is also on the board of directors of Skye. The same cast of characters that sold you EMH now bring you Skye Biosciences Inc.
  • J
    JamesBond
    Looks like investors like the arrangements. Hoping for better things.
  • R
    Razer Ramon
    Zombie company alert
  • J
    JamesBond
    Almost 2 million shares traded today, I have not seen volume like this for awhile. Wish the SP was a lot higher.
  • r
    rick
    it's moving.... anyone know why?
  • T
    Travis
    What an implosion.
  • B
    BTILC
    kiss your $ bye bye
  • J
    Joey
    COMPANY HIGHLIGHTS

    - Management & board members have raised over $1B for development-stage companies and run clinical trials with aggregate budgets exceeding $1B.

    - Entered into a strategic alliance with Factors R&D Technology, Inc, a division of Factors Group of Nutritional Companies Inc, Canada’s largest nutritional supplement marketer and manufacturer. The exclusive arrangement provides access to an industrial-scale production facility, capable of processing up to 1M kg of biomass annually and softgel production capacity of up to 600M capsules per year.

    - Secured cannabis supply agreements with the provinces of British Columbia, Ontario, Newfoundland and Labrador. Emerald will allocate approximately 13,000 kg of product to the BCLDB. Product quantities for the Ontario Cannabis Retail Corporation and the Newfoundland Labrador Liquor Corporation will be disclosed once details from these provinces are released.

    - Purchased 500 acres of harvested hemp chaff in 2018 and up to 1,000 acres in 2019 to 2022 from Emerald Health Hemp, Inc. CBD extract from hemp biomass will be used in Emerald’s medical and adult-use products.

    - Emerald is advancing its intellectual property portfolio through a recent research agreement with VivaCell Biotechnologies Spain and the filing of 17 provisional US patent applications. Emerald is developing unique cannabinoid formulations and dosage forms for precise and consistent medical-use and improved adult-use products. The Defined DoseTM formulations will be used in smoke, vape and edible Emerald products.
  • D
    Dewey
    VANCOUVER, British Columbia, April 03, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has signed a letter of intent to supply cannabis to the Société Québécoise du Cannabis (SQDC), Quebec's sole legal distributor of recreational cannabis. Under the agreement, Emerald will supply cannabis to the SQDC from its Québec-based Saint-Eustache facility, Verdélite, as well as from its 50%-owned joint venture, Pure Sunfarms, in Delta, BC. Emerald will fulfill its first supply order in Q2 2019.
    “Québec’s population of 8.4 million is a sizable market and we are pleased to be able to offer locally-grown, quality cannabis products to the adult-use consumers throughout the province,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “Verdélite is now near completion of the build-out of its 88,000 square foot indoor cultivation facility and has been scaling up production in licensed areas of the operation. We expect to be in full production and to also have nationwide distribution for the recreational market in the months ahead.”
  • B
    B
    BOSTON – A Canadian national residing in Long Beach, Calif., was arrested today and charged in connection with a securities fraud scheme in which he allegedly concealed his ownership of millions of shares in two companies for which he served as the chairman of the board of directors and then secretly directed the shares’ sale, generating approximately $2.19 million in proceeds.
    Avtar Singh Dhillon, 60, was charged in a criminal complaint with one count of conspiracy to commit securities fraud, one count of securities fraud and two counts of obstructing a proceeding of the U.S. Securities and Exchange Commission (SEC). Dhillon will make an initial appearance in federal court in Boston at a later date.
    According to the charging document, Dhillon, while serving as the chairman of two publicly-traded microcap companies, fraudulently concealed his beneficial ownership of millions of shares in those companies through two LLC entities created and managed by his attorney. One of the companies, Arch Therapeutics, Inc., was based in Framingham, Mass. It is alleged that Dhillon and his attorney concealed Dhillon’s ownership for the purpose of secretly selling the shares for Dhillon’s benefit in contravention of securities regulations that require disclosure of such sales and that limit the ability of company insiders to quickly sell large quantities of shares. Through their scheme, Dhillon and his attorney allegedly generated approximately $2.19 million in fraudulent proceeds. Later, when giving sworn testimony before the SEC, Dhillon allegedly twice withheld from investigators his beneficial interest in the LLC entities’ accounts and lied about his awareness of whether anyone had sold shares in Arch Therapeutics.
    The conspiracy charge and the securities fraud charge each provide for a sentence up to 25 years in prison, five years of supervised release and a fine of $250,000, or twice the gross gain or loss, whichever is greater. The charges of obstructing a proceeding of the U.S. Securities and Exchange Commission provide for sentences up to 20 years and five years in prison, respectively, three years of supervised release and a fine of $250,000. Sentences are imposed by a federal district court judge based upon the U.S. Sentencing Guidelines and other statutory factors.
    Acting United States Attorney Nathaniel R. Mendell and Joseph R. Bonavolonta, Special Agent in Charge of the Federal Bureau of Investigation, Boston Division made the announcement. The SEC and the SEC’s Boston Regional Office provided assistance with the investigation. Assistant U.S. Attorney James R. Drabick of Mendell’s Securities, Financial & Cyber Fraud Unit is prosecuting the case.
    The details contained in the charging documents are allegations. The defendant is presumed innocent unless and until proven guilty beyond a reasonable doubt in a court of law
  • l
    longongreen
    Standard processing license is a big win for the Verdélite facility- extraction is going to continue to grow imo- so popular right now- keep up to date on the best new plays from across the Canadian markets with SmallCapCanada, they always uncover the companies that are showing strong signs of growth and they deliver quality reports that are packed with insightful info and market analysis- just a great resource for any investor- SmallCapCanada
  • B
    BTILC
    Check this out: Opportunities For Emerald Health Continue To Expand After Expansion Of Production Capacity
    https://finance.yahoo.com/news/opportunities-emerald-health-continue-expand-113017600.html
  • T
    Tim
    Let’s stick to the facts. Emerald still owns 50% of PSF
    PSF just got access to Alberta’s 330 stores and online system
    PSF is the number one selling brand in Ontario
    Emerald is growing organic high quality bud that will retail above $15/gram
    And in 2020 will have organic outdoor low cost bud for high margin profits
    Emerald taught PSF/Village how to clone and propagate mj
    Village is failing at their hostile takeover attempts and probably violated SEC laws with their recent press releases
    Emerald will have a record breaking recovery in 2020 especially if they can find a new partner
  • C
    Christian Mercado
    This was actually a great idea by EMH not to exercise the right to buy at a discount. They allowed purefarms to sell at more of a profit and they took half. Speed to revenue.

    Recently Emerald Health Therapeutics ("Emerald") has been electing not to fully exercise its right under the Supply Agreement to purchase 40% of Pure Sunfarms' cannabis production. Pure Sunfarms has sold, and continues to sell, all portions of the production that Emerald did not purchase to other licensed producers in the spot market, where it has been realizing pricing in excess of the predetermined selling price to Emerald under this Supply Agreement.